Garmin has expanded its FDA-cleared and clinically-validated ECG app to additional smartwatches, including its flagship Epix Pro and Fēnix 7 Pro.

The app lets users record an ECG and check for signs of atrial fibrillation from their smartwatch.

The app is available on the Epix Pro, Fēnix 7 Pro, Venu 3 and Tactix 7 AMOLED edition smartwatches. The app lets users record their heart rhythm and check for signs of atrial fibrillation (AFib). Users in the USA can use the app to record a 30-second electrocardiogram (ECG) and view their heart rhythm results immediately on the watch or, optionally, later in the Garmin Connect smartphone app.

“We are pleased to bring the ECG app to even more of our customers, including those with our flagship Epix Pro and Fēnix 7 Pro series smartwatches,” said Dan Bartel, vice president of Swiss firm Garmin. “We take pride in offering premium health and wellness features across our smartwatch lines and this revolutionary tool that lets our customers conveniently take an ECG recording when they want only adds to the suite of innovative features to help them stay on top of their health.”

When users take an ECG, the app uses sensors on the smartwatch to record the electrical signals that control how their heart beats. The app then analyses that recording to detect signs of AFib. Additionally, users have the option to sync their results to Garmin Connect. Through the Garmin Connect app, they can view their history of results and create reports that can be shared with a health care provider.

The ECG app requires the latest version of the Garmin Connect smartphone app and smartwatch software before use. Garmin originally announced the ECG app for Venu 2 Plus users in January.

The ECG app is not intended for use by people under 22 years old. With the app, a compatible smartwatch is capable of generating an ECG similar to a single-lead electrocardiogram.

Garmin (www.garmin.com) is incorporated in Switzerland, and its principal subsidiaries are in the USA, Taiwan and the UK.